TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02403713
Drug: Fluticasone/formoterol PMDI with spacer
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone/Formoteral 125/5µg pMDI with spacer
Study: NCT02403713
Drug: Fluticasone/formoterol PMDI without spacer low dose
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone/Formoteral 125/5µg pMDI without spacer, low dose
Study: NCT01978600
Drug: Brinzolamide 1%/Brimonidine 0.2% ophthalmic suspension
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Commercially marketed and approved for lowering IOP in patients with open-angle glaucoma and ocular hypertension.
Study: NCT01978600
Drug: Timolol Maleate 0.5%
Normalized name: TIMOLOL MALEATE 0.5% GEL,OPH
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Commercially marketed and approved for lowering IOP in patients with open-angle glaucoma and ocular hypertension.
Study: NCT03588936
Drug: Nivolumab (.25 mg/kg)
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive Nivolumab at one of two dose levels every 2 weeks for 4 treatments.
Study: NCT03588936
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive 2 doses of tocilizumab
Study: NCT01022151
Drug: 0.2 mL/kg of aminophylline 20 mg/mL [group A4]
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: receive intravenous injection of 0.2 mL/kg of aminophylline 20 mg/mL \[group A4\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
Study: NCT01022151
Drug: 0.2 mL/kg of aminophylline 25 mg/mL [group A5]
DrugBank: Aminophylline (DB01223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: receive intravenous injection of 0.2 mL/kg of aminophylline 25 mg/mL \[group A5\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
Study: NCT00481572
Drug: Terlipressin
Normalized name: Terlipressin
DrugBank: Terlipressin (DB02638)
Approvals — FDA: no, EMA: no, PMDA: no
Description: continuous terlipressin infusion 1.3 µg•kg-1 over a period of 48 hrs
Study: NCT00481572
Drug: Vasopressin
Normalized name: Vasopressin
DrugBank: Vasopressin (DB00067)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: continuous intravenous infusion of vasopressin 0.03 U•min-1 over a period of 48 hrs
Study: NCT01022151
Drug: Doxapram 1 mg/kg [group D]
DrugBank: Doxapram (DB00561)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: receive intravenous injection of 0.2 mL/kg of doxapram 5 mg/mL \[group D\]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
Study: NCT00143806
Drug: Transitioning patients from cyclosporine to alefacept
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03588936
Drug: Nivolumab (.5 mg/kg)
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive Nivolumab at one of two dose levels every 2 weeks for 4 treatments.
Study: NCT03735264
Drug: Anlotinib Hydrochloride plus Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anlotinib Hydrochloride (12mg QD PO d1-14, 21 days per cycle) and Docetaxel (75mg/m2 IV d1)
Study: NCT01833455
Drug: PVC Suppression using Flecainide
DrugBank: Flecainide (DB01195)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Flecainide will be administered to result in a reduction in PVC burden.
Study: NCT00333164
Drug: Asprin, Cilostazol
DrugBank: Cilostazol (DB01166)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01529125
Drug: zidovudine, lamivudine, nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02966756
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tablet; Oral
Study: NCT00618254
Drug: Granisetron
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03883828
Drug: Chlorhexidine gluconate solution
Normalized name: chlorhexidine gluconate Irrigation Solution
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in the intervention arm will receive a decolonization regimen, consisting of intranasal mupirocin ointment to be applied twice daily to the nares and chlorhexidine wash to be used once daily to the body.
Study: NCT03883828
Drug: Mupirocin Ointment
Normalized name: Mupirocin Ointment
DrugBank: Mupirocin (DB00410)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in the intervention arm will receive a decolonization regimen, consisting of intranasal mupirocin ointment to be applied twice daily to the nares and chlorhexidine wash to be used once daily to the body.
Study: NCT01673399
Drug: Atosiban
Normalized name: atosiban
DrugBank: Atosiban (DB09059)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Bolus atosiban 6.75mg + infusion atosiban 18mg/u during 3 hours. once administered starting 1 hour before embryotransfer.
Study: NCT00759798
Drug: Fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg/m\^2 given intravenously on Days 2-4 of Cycle 1 and Days 1-3 of Cycles 2 and beyond.
Study: NCT00759798
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m2 given intravenously on Day 1 of Course 1~All subsequent Courses: 500 mg/m2 given intravenously on Day 1 (Weeks 5,9,13,17,21)
Study: NCT01006057
Drug: insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with end stage renal disease
Study: NCT01006057
Drug: insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with mild renal impairment
Study: NCT01006057
Drug: insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with moderate renal impairment
Study: NCT01006057
Drug: insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in healthy volunteers
Study: NCT01006057
Drug: insulin degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with severe renal impairment
Study: NCT03258398
Drug: Avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab 10 mg/kg will be administered intravenously (IV) on Day 1 and once every 2 weeks (q2wk) thereafter
Study: NCT02162121
Drug: Mepivacaine 1%
Normalized name: mepivacaine 1% injectable solution
DrugBank: Mepivacaine (DB00961)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02162121
Drug: Levobupivacaine 0,5%
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02162121
Drug: Ropivacaine 0,2%
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02162121
Drug: Buprenorphine 0,2mg
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00109772
Drug: lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Two 5 mg capsules taken one time per day
Study: NCT01989754
Drug: Canagliflozin, 100 mg
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One 100 mg capsule taken orally (by mouth) once daily
Study: NCT01989754
Drug: Canagliflozin, 300 mg
DrugBank: Canagliflozin (DB08907)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One 300 mg capsule taken orally (by mouth) once daily
Study: NCT02516150
Drug: Glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: injection of 50 micrograms of glucagon
Study: NCT00201981
Drug: Rebamipide
Normalized name: Rebamipide
DrugBank: Rebamipide (DB11656)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 1. OPC as a single drop per eye (approx 50 µL) 4 times per day for 52 weeks~2. OPC as a single drop per eye (approx 50 µL) 4 times per day for 52 weeks
Study: NCT02151682
Drug: Morphine prolonged release
Normalized name: morphine Extended Release Oral Tablet
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02316626
Drug: Subcutaneous progesterone
Normalized name: Progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 25 mg daily for 14 days
Study: NCT02316626
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 90 mg daily for 14 days
Study: NCT00618995
Drug: Comparator: ER niacin (+) laropiprant
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ER niacin 2 g/ laropiprant 40 mg daily for 7 days.
Study: NCT00618995
Drug: Comparator: ER niacin
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ER niacin 2 g daily for 7 days.
Study: NCT00618995
Drug: Comparator: laropiprant
DrugBank: Laropiprant (DB11629)
Approvals — FDA: no, EMA: no, PMDA: no
Description: laropiprant 40 mg daily for 7 days.
Study: NCT01779050
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03634917
Drug: Acamprosate Calcium
Normalized name: Acamprosate Calcium
DrugBank: Acamprosate (DB00659)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 capsule with 666 mg Acamprosate
Study: NCT03634917
Drug: Calcium Carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 capsule with 1500 mg Calcium Carbonate
Study: NCT01779050
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01779050
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01779050
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04913480
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Durvalumab 750mg intravenous infusion once every 2 weeks for 26 cycles
Study: NCT00942344
Drug: Amlodipine plus Losartan
Normalized name: losartan and amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amlodipine/losartan 5/50mg, 5/100mg, 10/50mg, 10/100mg
Study: NCT00942344
Drug: Amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amlodipine 5mg, 10mg
Study: NCT00942344
Drug: Losartan
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Losartan 50mg, 100mg
Study: NCT00077935
Drug: Civamide
Normalized name: Civamide
DrugBank: Zucapsaicin (DB09120)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream 0.075%, TID for 52 weeks
Study: NCT00385606
Drug: gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00385606
Drug: prolonged continuous infusion gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00385606
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00815100
Drug: Ivabradine
Normalized name: Ivabradine
DrugBank: Ivabradine (DB09083)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Eligible patients will be randomized to 1 of the 2 treatment arms, namely, double-blind ivabradine, or placebo, after hospital admission (at 48 hours). The starting dose of ivabradine will be 5 mg (or matching placebo) twice daily in all patients. Patients receiving 5 mg twice daily (or matching placebo) 1 week after the inclusion with a resting HR of ≥60 beats per minute will receive the target dose of 7.5 mg twice daily (or matching placebo).
Study: NCT04235205
Drug: Elobixibat 10mg + cholestyramine powder 9g (cholestyramine 4g)
DrugBank: Cholestyramine (DB01432)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with nonalcoholic fatty liver disease are administered Elobixibat 10mg + cholestyramine powder 9g (cholestyramine 4g) for 16 weeks
Study: NCT04235205
Drug: Elobixibat 10mg + cholestyramine powder placebo
Normalized name: cholestyramine resin
DrugBank: Cholestyramine (DB01432)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with nonalcoholic fatty liver disease are administered Elobixibat 10mg+ cholestyramine powder placebo for 16 weeks
Study: NCT04235205
Drug: Elobixibat placebo + cholestyramine powder 9g (cholestyramine 4g)
DrugBank: Cholestyramine (DB01432)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with nonalcoholic fatty liver disease are administered Elobixibat placebo+ cholestyramine powder 9g (cholestyramine 4g) for 16 weeks
Study: NCT04235205
Drug: Elobixibat placebo + cholestyramine powder placebo
DrugBank: Cholestyramine (DB01432)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients with nonalcoholic fatty liver disease are administered Elobixibat placebo+ cholestyramine powder placebo for 16 weeks
Study: NCT02522598
Drug: VVZ-149 injections
Normalized name: Vvz-149 free base
DrugBank: Opiranserin (DB16271)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colorless, transparent liquid in water for injection
Study: NCT03513757
Drug: propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: propofol 2 mg/kg at start of procedure; 2 mg/kg for movement, 150-300 mcg/kg/minute propofol infusion if movement persists
Study: NCT03513757
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: single dose dexmedetomidine administered at start of sedation in the propofol-dexmedetomidine group. Dosing is based upon anticipated duration of scan from 30 - 75 minutes and will range from 0.5 mic/kg to 1.25 mcg/kg
Study: NCT03513757
Drug: Glycopyrrolate
Normalized name: Glycopyrrolate
DrugBank: Glycopyrronium (DB00986)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mcg/kg glycopyrrolate will be administered at the start of sedation in the propofol-dexmedetomidine group
Study: NCT03513757
Drug: Lidocaine 1% Injectable Solution
Normalized name: lidocaine 1% injectable solution
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg/kg intravenous administration prior to propofol administration
Study: NCT03513757
Drug: Nitrous Oxide
Normalized name: Nitrous Oxide
DrugBank: Nitrous oxide (DB06690)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhalation of nitrous oxide may be used for IV placement
Study: NCT03513757
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhalation of sevoflurane may be used for IV placement
Study: NCT01044446
Drug: Icodextrin
Normalized name: Icodextrin
DrugBank: Icodextrin (DB00702)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one exchange daily
Study: NCT01080456
Drug: Tacrolimus 1 mg capsule
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
Study: NCT02186457
Drug: Polymyxin B in Normal Saline
Normalized name: NS-2359
DrugBank: Polymyxin B (DB00781)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic irrigation via peritoneal lavage
Study: NCT04671069
Drug: Clopidogrel
Normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: After one-day washout period after Day 1, loading dose of 300 mg clopidogrel administered on Day 3 and then, at approximately the same time each morning, 75 mg clopidogrel administered on Days 4 to 11
Study: NCT00255957
Drug: HES administration
Normalized name: HE-2200
DrugBank: HE-2200 (DB06257)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03846102
Drug: Levobupivacaine
Normalized name: Levobupivacaine
DrugBank: Levobupivacaine (DB01002)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levobupivacaïne for injection 7.5 mg/kg diluted with Sodium Chloride 0,9%
Study: NCT03846102
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Morphine 1 mg/ml solution for infusion.
Study: NCT03652974
Drug: sodium valproate with Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sodium valproate may be used as a synergistic agent of clozapine in the treatment of treatment-refractory schizophrenia
Study: NCT03652974
Drug: amisulpride with Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amisulpride may be used as a synergistic agent of clozapine in the treatment of treatment-refractory schizophrenia
Study: NCT03652974
Drug: placebo with Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: placebo may be used as a synergistic agent of clozapine in the treatment of treatment-refractory schizophrenia
Study: NCT02170025
Drug: Riociguat (Adempas, BAY63-2521)
Normalized name: Riociguat
DrugBank: Riociguat (DB08931)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants received 0.5 mg BAY63-2521 three times daily (tid) for 14 days. The dose would be increased to 1 mg BAY63-2521 for an additional 14 days, if this was considered safe and tolerable on the basis of the available data for a given patient.
Study: NCT01389193
Drug: Ibudilast
Normalized name: ibudilast
DrugBank: Ibudilast (DB05266)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Ibudilast 40 mg twice daily oral capsules for a duration of 8 weeks
Study: NCT01369225
Drug: AAB-003 (PF-05236812)
Normalized name: insulin lispro-aabc
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 0.5 mg/kg AAB-003, IV
Study: NCT01369225
Drug: AAB-003 (PF-05236812)
Normalized name: insulin lispro-aabc
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 mg/kg AAB-003, IV
Study: NCT01369225
Drug: AAB-003 (PF-05236812)
Normalized name: insulin lispro-aabc
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 mg/kg AAB-003, IV
Study: NCT01369225
Drug: AAB-003 (PF-05236812)
Normalized name: insulin lispro-aabc
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4 mg/kg AAB-003, IV
Study: NCT01369225
Drug: AAB-003 (PF-05236812)
Normalized name: insulin lispro-aabc
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 8 mg/kg AAB-003, IV
Study: NCT00168064
Drug: mechlorethamine-MCH (nitrogen mustard)
DrugBank: Mechlorethamine (DB00888)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All affected areas (lesions) are to be treated once daily for twelve months with mechlorethamine-MCH (nitrogen mustard) 0.02% PG or NM 0.02% AP ointment
Study: NCT00082329
Drug: AMD 3100 (Mozobil plerixafor)
Normalized name: AMD
DrugBank: Methyldopa (DB00968)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants received subcutaneous injection of granulocyte colony-stimulating factor (G-CSF) at 10 mcg/kg/day for 5 days followed by a single subcutaneous injection of AMD3100 (240 mcg/kg) given 12 hours prior to apheresis peripheral blood stem cell collection. Peripheral blood stem cell collection performed on the fifth day of G-CSF administration.
Study: NCT00082329
Drug: Granulocyte colony-stimulating factor (G-CSF)
Normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants received subcutaneous injection of granulocyte colony-stimulating factor (G-CSF) at 10 mcg/kg/day for 5 days followed by a single subcutaneous injection of AMD3100 (240 mcg/kg) given 12 hours prior to apheresis peripheral blood stem cell collection. Peripheral blood stem cell collection performed on the fifth day of G-CSF administration.
Study: NCT01489189
Drug: 0.5-mg Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal injection of 0.5 mg ranibizumab (Lucentis™) at baseline and up to every 4 weeks using defined retreatment criteria.
Study: NCT03234972
Drug: Daratumumab
Normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daratumumab will be administered on Day 1 of Cycles 4-9, and then q4w thereafter.
Study: NCT03234972
Drug: Velcade
Normalized name: Velcade
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Velcade will be administered at a dose of 1.3 mg/m\^2 SC on Days 1, 4, 8 and 11 of each 21-day cycle.
Study: NCT03234972
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dex will be administered orally at 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 of the first 8 Velcade treatment cycles.
Study: NCT00646568
Drug: s.c. human chorionic gonadotropin (Pregnyl)
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S.C. Pregnyl 10000 IU once
Study: NCT01743885
Drug: Acebutolol
Normalized name: Acebutolol
DrugBank: Acebutolol (DB01193)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg/kg/jour in 2 doses during 90 days after gradual increase of doses in the first week
Study: NCT01743885
Drug: Propanolol
Normalized name: Propanolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3 mg/kg/jour in 3 doses during 90 days after gradual increase of doses in the first week
Study: NCT02465255
Drug: Tramadol
Normalized name: Tramadol
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03823807
Drug: SH-1028
Normalized name: Glutathione-SH
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral,100mg or 200mg ,QD, fasted
Study: NCT01858896
Drug: Glucagon-Like Peptide- 1 (GLP-1) infusion
Normalized name: Glucagon-like peptide II (2-glycine) (human)
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: GLP-1 infusion during experimental period
Study: NCT03000634
Drug: Elotuzumab
Normalized name: elotuzumab
DrugBank: Elotuzumab (DB06317)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered through a small tube that goes directly into the vein
Study: NCT03000634
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Administered as a subcutaneous injection under the skin
Study: NCT03000634
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Capsule taken by mouth